Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rocket One Inc.HOTH · Entity 7736 | Chief Financial Officer | March 06, 2019 | March 07, 2019 |
| Unique Logistics International, Inc.UNQL · Entity 79750 | Director | May 14, 2025 | May 15, 2025 |
| ZyVersa Therapeutics, Inc.LSPR · Entity 8639 | Director · Chief Financial Officer | January 06, 2022 | March 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rocket One Inc.
Report date March 06, 2019 · Filed March 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2024-03-06 | Direct | 50,000 |
Reported balance
After 2019-03-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-06 · Other · Acquired 50,000 · Balance 50,000 F1: The options were issued pursuant to the Issuer's 2018 Equity Incentive Plan and vested in full upon grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were issued pursuant to the Issuer's 2018 Equity Incentive Plan and vested in full upon grant.
Unique Logistics International, Inc.
Report date May 14, 2025 · Filed May 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Convertible Preferred StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-14 transaction · row 1
1 source rowRow 1 · 2025-05-14 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger by and among Unique Logistics International, Inc., ("UNQL"), DP World Logistics US Holdings, Inc. ("Parent"), and Unique Merger Co., a wholly owned subsidiary of Parent, dated March 11, 2025, Unique Merger Co. merged with and into UNQL, with UNQL surviving as a wholly owned subsidiary of Parent. At the effective time of the merger, each share of Series A Convertible Preferred Stock converted into the right to receive a lump-sum cash payment equal to $0.0037 per share of Common Stock, multiplied by 9,677.1581, the number of shares of Common Stock issuable upon conversion of each Series A share pursuant to its Certificate of Designation, including applicable anti-dilution provisions. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger by and among Unique Logistics International, Inc., ("UNQL"), DP World Logistics US Holdings, Inc. ("Parent"), and Unique Merger Co., a wholly owned subsidiary of Parent, dated March 11, 2025, Unique Merger Co. merged with and into UNQL, with UNQL surviving as a wholly owned subsidiary of Parent. At the effective time of the merger, each share of Series A Convertible Preferred Stock converted into the right to receive a lump-sum cash payment equal to $0.0037 per share of Common Stock, multiplied by 9,677.1581, the number of shares of Common Stock issuable upon conversion of each Series A share pursuant to its Certificate of Designation, including applicable anti-dilution provisions.
ZyVersa Therapeutics, Inc.
Report date January 06, 2022 · Filed March 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Indirectsee footnote | 10,752 |
Reported balance
After 2022-01-06 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-01-06 · Other · Acquired 10,752 · Balance 10,752 F1: These shares are underlying units (each unit consisting of one share of Class A common stock and three-fourths of one warrant, each whole warrant exercisable to purchase one share of Class A common stock) acquired in a private placement by the Larkspur Health LLC (the "Sponsor") in connection with the issuer's initial public offering and subsequent partial exercise of the underwriters' over-allotment option. The above refers to the shares of Class A common stock included in the units purchased. F2: The shares represent those owned by Mr. Briones, a member of Larkspur Health LLC based on his pro rata share of ownership of Larkspur Health LLC. |
| Class B common stockSEC Table II · derivative / convertible security | Indirectsee footnote | 55,967 |
Reported balance
After 2022-01-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-06 · Other · Disposed 1,533 · Balance 55,967 F3: As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the "Registration Statement") under the section entitled "Description of Securities - Founder Shares," the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date F4: As contemplated in connection with the initial public offering of the Issuer, 22,343 shares of Class B common stock of the Issuer were forfeited for no consideration and cancelled because the underwriters of the Issuer's initial public offering did not exercise their over-allotment option in full, as described in the Issuer's Registration Statement. F2: The shares represent those owned by Mr. Briones, a member of Larkspur Health LLC based on his pro rata share of ownership of Larkspur Health LLC. |
| Class B common stockSEC Table II · derivative / convertible security | Indirectsee footnote | 56,123 |
Reported balance
After 2022-01-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-01-06 · Other · Acquired 91 · Balance 56,123 F3: As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the "Registration Statement") under the section entitled "Description of Securities - Founder Shares," the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date F5: In connection with the partial exercise of the underwriters' over-allotment option, A.G.P./Alliance Global Partners transferred 3,427 shares to the Sponsor for no consideration. F2: The shares represent those owned by Mr. Briones, a member of Larkspur Health LLC based on his pro rata share of ownership of Larkspur Health LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are underlying units (each unit consisting of one share of Class A common stock and three-fourths of one warrant, each whole warrant exercisable to purchase one share of Class A common stock) acquired in a private placement by the Larkspur Health LLC (the "Sponsor") in connection with the issuer's initial public offering and subsequent partial exercise of the underwriters' over-allotment option. The above refers to the shares of Class A common stock included in the units purchased.
F2: The shares represent those owned by Mr. Briones, a member of Larkspur Health LLC based on his pro rata share of ownership of Larkspur Health LLC.
F3: As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the "Registration Statement") under the section entitled "Description of Securities - Founder Shares," the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date
F4: As contemplated in connection with the initial public offering of the Issuer, 22,343 shares of Class B common stock of the Issuer were forfeited for no consideration and cancelled because the underwriters of the Issuer's initial public offering did not exercise their over-allotment option in full, as described in the Issuer's Registration Statement.
F5: In connection with the partial exercise of the underwriters' over-allotment option, A.G.P./Alliance Global Partners transferred 3,427 shares to the Sponsor for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2025 Filed May 15, 2025 10:26 UTC | Unique Logistics International, Inc. UNQL · Entity 79750 | Disposition to issuerSeries A Convertible Preferred Stock | 20,000 | $35.81 | $716,110.00 |
DisclosureSEC source: 0001641172-25-010601 · ownership.xml · nonDerivative · entry 1 Briones David S. · CIK 0001599831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger by and among Unique Logistics International, Inc., ("UNQL"), DP World Logistics US Holdings, Inc. ("Parent"), and Unique Merger Co., a wholly owned subsidiary of Parent, dated March 11, 2025, Unique Merger Co. merged with and into UNQL, with UNQL surviving as a wholly owned subsidiary of Parent. At the effective time of the merger, each share of Series A Convertible Preferred Stock converted into the right to receive a lump-sum cash payment equal to $0.0037 per share of Common Stock, multiplied by 9,677.1581, the number of shares of Common Stock issuable upon conversion of each Series A share pursuant to its Certificate of Designation, including applicable anti-dilution provisions. Read SEC document |
| January 06, 2022 Filed Mar 10, 2022 17:30 UTC | ZyVersa Therapeutics, Inc. LSPR · Entity 8639 | OtherClass B common stock · Derivative | 91 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-011641 · ownership.xml · derivative · entry 3 Briones David S. · CIK 0001599831 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 56,123 Underlying: Class A common stock · 156 shares Expires not disclosed F3 · security: As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the "Registration Statement") under the section entitled "Description of Securities - Founder Shares," the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date F3 · derivative.exercise_price: As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the "Registration Statement") under the section entitled "Description of Securities - Founder Shares," the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date F3 · kind: As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the "Registration Statement") under the section entitled "Description of Securities - Founder Shares," the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date F5 · shares: In connection with the partial exercise of the underwriters' over-allotment option, A.G.P./Alliance Global Partners transferred 3,427 shares to the Sponsor for no consideration. F3 · derivative.exercise_date: As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the "Registration Statement") under the section entitled "Description of Securities - Founder Shares," the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date F3 · derivative.expiration_date: As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the "Registration Statement") under the section entitled "Description of Securities - Founder Shares," the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date F2 · ownership.direct: The shares represent those owned by Mr. Briones, a member of Larkspur Health LLC based on his pro rata share of ownership of Larkspur Health LLC. Read SEC document |
| January 06, 2022 Filed Mar 10, 2022 17:30 UTC | ZyVersa Therapeutics, Inc. LSPR · Entity 8639 | OtherClass B common stock · Derivative | 1,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-011641 · ownership.xml · derivative · entry 2 Briones David S. · CIK 0001599831 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 55,967 Underlying: Class A common stock · 1,533 shares Expires not disclosed F3 · security: As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the "Registration Statement") under the section entitled "Description of Securities - Founder Shares," the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date F3 · derivative.exercise_price: As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the "Registration Statement") under the section entitled "Description of Securities - Founder Shares," the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date F3 · kind: As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the "Registration Statement") under the section entitled "Description of Securities - Founder Shares," the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date F4 · shares: As contemplated in connection with the initial public offering of the Issuer, 22,343 shares of Class B common stock of the Issuer were forfeited for no consideration and cancelled because the underwriters of the Issuer's initial public offering did not exercise their over-allotment option in full, as described in the Issuer's Registration Statement. F3 · derivative.exercise_date: As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the "Registration Statement") under the section entitled "Description of Securities - Founder Shares," the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date F3 · derivative.expiration_date: As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the "Registration Statement") under the section entitled "Description of Securities - Founder Shares," the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date F2 · ownership.direct: The shares represent those owned by Mr. Briones, a member of Larkspur Health LLC based on his pro rata share of ownership of Larkspur Health LLC. Read SEC document |
| January 06, 2022 Filed Mar 10, 2022 17:30 UTC | ZyVersa Therapeutics, Inc. LSPR · Entity 8639 | OtherClass A Common Stock | 10,752 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-011641 · ownership.xml · nonDerivative · entry 1 Briones David S. · CIK 0001599831 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 10,752 F1 · security: These shares are underlying units (each unit consisting of one share of Class A common stock and three-fourths of one warrant, each whole warrant exercisable to purchase one share of Class A common stock) acquired in a private placement by the Larkspur Health LLC (the "Sponsor") in connection with the issuer's initial public offering and subsequent partial exercise of the underwriters' over-allotment option. The above refers to the shares of Class A common stock included in the units purchased. F1 · kind: These shares are underlying units (each unit consisting of one share of Class A common stock and three-fourths of one warrant, each whole warrant exercisable to purchase one share of Class A common stock) acquired in a private placement by the Larkspur Health LLC (the "Sponsor") in connection with the issuer's initial public offering and subsequent partial exercise of the underwriters' over-allotment option. The above refers to the shares of Class A common stock included in the units purchased. F2 · ownership.nature: The shares represent those owned by Mr. Briones, a member of Larkspur Health LLC based on his pro rata share of ownership of Larkspur Health LLC. Read SEC document |
| March 06, 2019 Filed Mar 7, 2019 16:33 UTC | Rocket One Inc. HOTH · Entity 7736 | OtherOptions · Derivative | 50,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001213900-19-003749 · ownership.xml · derivative · entry 1 Briones David S. · CIK 0001599831 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2024-03-06 F1 · kind: The options were issued pursuant to the Issuer's 2018 Equity Incentive Plan and vested in full upon grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.